Pace Diagnostics
Emerging biotechnology company focused on research, development, licensing, manufacturing and commercialization of point-of-care rapid diagnostics. The organization develops biomarker-driven diagnostic platforms and assays aimed at affordable, non‑invasive, accessible early detection and screening for tuberculosis, SARS‑CoV‑2 (antigen) and lung cancer. The company reports formation on decades of research and support from U.S. federal grants and contracts.
Industries
Nr. of Employees
small (1-50)
Pace Diagnostics
Products
Tuberculosis triage/screening test
A point-of-care rapid diagnostic intended to triage and screen patients for tuberculosis infection or disease.
SARS-CoV-2 antigen rapid detection test
A rapid antigen detection assay for SARS-CoV-2 designed for point-of-care use to detect viral proteins.
Lung cancer early-detection test
A non-invasive early-detection diagnostic assay for lung cancer intended to identify disease at an earlier, more treatable stage.
Tuberculosis triage/screening test
A point-of-care rapid diagnostic intended to triage and screen patients for tuberculosis infection or disease.
SARS-CoV-2 antigen rapid detection test
A rapid antigen detection assay for SARS-CoV-2 designed for point-of-care use to detect viral proteins.
Lung cancer early-detection test
A non-invasive early-detection diagnostic assay for lung cancer intended to identify disease at an earlier, more treatable stage.
Expertise Areas
- Point-of-care diagnostic development
- Biomarker discovery and assay development
- Infectious disease diagnostics (tuberculosis, SARS-CoV-2)
- Cancer early detection (lung cancer)
Key Technologies
- Point-of-care rapid diagnostic platforms
- Antigen-based rapid tests
- Biomarker-based assay development
- Screening/triage diagnostic assays
News & Updates
Raised over $150,000 through a Wefunder investment campaign to support company development.
Raised over $150,000 through a Wefunder investment campaign to support company development.